Physician profile
Dana Landry
NPI 1437361755
$3,400.44
in general payments reported to CMS, 2019-2025
20 companies · $97.20 in 2025
The $97.20 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,628 · 2022: $846 · 2023: $368 · 2024: $461 · 2025: $97.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $683.95 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $507.29 | 2021-2024 | Rexulti |
| Lundbeck LLC | $449.50 | 2021-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $253.89 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $250.55 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $211.78 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $151.95 | 2021-2022 | |
| Alkermes, INC. | $150.00 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $146.05 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $140.58 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $113.15 | 2021-2022 | |
| Bausch Health US, LLC | $101.15 | 2021 | |
| Abbvie INC. | $89.63 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $32.18 | 2021 | |
| Adlon Therapeutics L.P. | $30.47 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.12 | 2022 | |
| Alfasigma USA, INC. | $19.06 | 2021 | |
| Almatica Pharma LLC | $17.18 | 2022 | |
| Corium, LLC | $15.24 | 2021 | |
| Neurocrine Biosciences, INC. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Landry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.